Education
About Us
Working with TipRanks
Follow Us
Oxford BioMedica plc (GB:OXB)
LSE:OXB
Earnings Data
Report Date
Apr 09, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-7.7Last Year’s EPS
-113.4Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Sep 23, 2024
|% Change Since: 16.80%
|Next Earnings Date:Apr 09, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant revenue growth, increased client orders, operational efficiency improvements, and strategic expansions. However, challenges such as the operating EBITDA loss and negative working capital movement were noted.Company Guidance
In the 2024 analyst briefing, OXB reported strong financial performance with an impressive organic revenue growth of 81%, resulting in total revenues of GBP128.8 million, a 44% increase from the previous year. Their pipeline expanded by 30% to $570 million, and customer orders grew by 35% to GBP186 million. The company achieved an operating EBITDA profit of GBP5 million in the second half of the year, narrowing their annual operating EBITDA loss to GBP15.3 million, a significant improvement from 2023's GBP52.8 million loss. For 2025, OXB expects revenues between GBP160 million and GBP170 million, with over 80% of this already covered by existing orders. The company plans to achieve a low single-digit million operating EBITDA profit, with a focus on continued margin expansion driven by operational efficiencies and strong commercial momentum.Impressive Organic Revenue Growth
The company achieved an organic revenue growth of 81% and total revenues increased by 44% to GBP128.8 million in 2024.
Record Client Orders
The contracted value of client orders reached GBP186 million in 2024, a 35% increase from the previous year.
Operational Efficiency
Operating EBITDA loss narrowed significantly from GBP52.8 million in 2023 to GBP15.3 million in 2024, with a GBP5 million operating EBITDA profit in the second half of 2024.
Strong Commercial Momentum
The company reported significant growth in its pipeline, with a risk-adjusted pipeline growth of 61% from 2022 to 2024.
Successful FDA Inspection
The FDA inspection of the Oxford manufacturing site in July 2024 resulted in zero written observations, highlighting the quality management system.
Strategic Expansion and Rebranding
Completed acquisition of OXB in France, expanding operational footprint, and rebranded as OXB establishing a unified brand across geographies.
---
GB:OXB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:OXB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 09, 2025 | 256.00p | 232.50p | -9.18% |
| Sep 23, 2024 | 357.00p | 360.00p | +0.84% |
| Apr 29, 2024 | 228.50p | 260.00p | +13.79% |
| Sep 20, 2023 | 241.50p | 269.00p | +11.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Oxford BioMedica plc (GB:OXB) report earnings?
Oxford BioMedica plc (GB:OXB) is schdueled to report earning on Apr 09, 2025, TBA Not Confirmed.
What is Oxford BioMedica plc (GB:OXB) earnings time?
Oxford BioMedica plc (GB:OXB) earnings time is at Apr 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Oxford BioMedica plc stock?
The P/E ratio of Oxford BioMedica is N/A.
What is GB:OXB EPS forecast?
GB:OXB EPS forecast for the fiscal quarter 2024 (Q4) is -7.7.
---